vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and PARK NATIONAL CORP (PRK). Click either name above to swap in a different company.
PARK NATIONAL CORP is the larger business by last-quarter revenue ($168.3M vs $86.8M, roughly 1.9× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 2.2%). PARK NATIONAL CORP produced more free cash flow last quarter ($191.9M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 4.9%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
National Retail Systems, Inc. (NRS) includes Keystone Freight Corp. & National Retail Transportation, Inc. (NRT). NRS is an asset based 3PL founded in 1952. It is headquartered in Lyndhurst, New Jersey, United States.
IOVA vs PRK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $168.3M |
| Net Profit | — | $42.6M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | — |
| Net Margin | — | 25.3% |
| Revenue YoY | 17.7% | 2.2% |
| Net Profit YoY | — | 10.4% |
| EPS (diluted) | — | $2.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $168.3M | ||
| Q3 25 | $67.5M | $169.5M | ||
| Q2 25 | $60.0M | $168.7M | ||
| Q1 25 | $49.3M | $157.9M | ||
| Q4 24 | $73.7M | $164.7M | ||
| Q3 24 | $58.6M | $170.3M | ||
| Q2 24 | $31.1M | $157.7M | ||
| Q1 24 | $715.0K | $152.8M |
| Q4 25 | — | $42.6M | ||
| Q3 25 | $-91.3M | $47.2M | ||
| Q2 25 | $-111.7M | $48.1M | ||
| Q1 25 | $-116.2M | $42.2M | ||
| Q4 24 | — | $38.6M | ||
| Q3 24 | $-83.5M | $38.2M | ||
| Q2 24 | $-97.1M | $39.4M | ||
| Q1 24 | $-113.0M | $35.2M |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -84.7% | — | ||
| Q3 25 | -140.7% | 34.3% | ||
| Q2 25 | -189.8% | 35.2% | ||
| Q1 25 | -245.8% | 32.4% | ||
| Q4 24 | -117.5% | — | ||
| Q3 24 | -152.1% | 27.4% | ||
| Q2 24 | -327.6% | 30.6% | ||
| Q1 24 | -16464.6% | 27.8% |
| Q4 25 | — | 25.3% | ||
| Q3 25 | -135.3% | 27.8% | ||
| Q2 25 | -186.2% | 28.5% | ||
| Q1 25 | -235.5% | 26.7% | ||
| Q4 24 | — | 23.5% | ||
| Q3 24 | -142.7% | 22.4% | ||
| Q2 24 | -312.2% | 25.0% | ||
| Q1 24 | -15800.8% | 23.0% |
| Q4 25 | — | $2.62 | ||
| Q3 25 | — | $2.92 | ||
| Q2 25 | $-0.33 | $2.97 | ||
| Q1 25 | $-0.36 | $2.60 | ||
| Q4 24 | $-0.24 | $2.38 | ||
| Q3 24 | $-0.28 | $2.35 | ||
| Q2 24 | $-0.34 | $2.42 | ||
| Q1 24 | $-0.42 | $2.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $233.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $1.4B |
| Total Assets | $913.2M | $9.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $233.5M | ||
| Q3 25 | $300.8M | $218.9M | ||
| Q2 25 | $301.2M | $193.1M | ||
| Q1 25 | $359.7M | $237.6M | ||
| Q4 24 | $323.8M | $160.6M | ||
| Q3 24 | $397.5M | $201.7M | ||
| Q2 24 | $412.5M | $261.5M | ||
| Q1 24 | $356.2M | $306.1M |
| Q4 25 | $698.6M | $1.4B | ||
| Q3 25 | $702.3M | $1.3B | ||
| Q2 25 | $698.5M | $1.3B | ||
| Q1 25 | $767.9M | $1.3B | ||
| Q4 24 | $710.4M | $1.2B | ||
| Q3 24 | $773.5M | $1.2B | ||
| Q2 24 | $768.5M | $1.2B | ||
| Q1 24 | $680.0M | $1.2B |
| Q4 25 | $913.2M | $9.8B | ||
| Q3 25 | $904.9M | $9.9B | ||
| Q2 25 | $907.4M | $9.9B | ||
| Q1 25 | $966.7M | $9.9B | ||
| Q4 24 | $910.4M | $9.8B | ||
| Q3 24 | $991.1M | $9.9B | ||
| Q2 24 | $964.3M | $9.9B | ||
| Q1 24 | $869.8M | $9.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $198.3M |
| Free Cash FlowOCF − Capex | $-61.9M | $191.9M |
| FCF MarginFCF / Revenue | -71.3% | 114.1% |
| Capex IntensityCapex / Revenue | 10.7% | 3.8% |
| Cash ConversionOCF / Net Profit | — | 4.65× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $328.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $198.3M | ||
| Q3 25 | $-78.7M | $52.6M | ||
| Q2 25 | $-67.4M | $49.7M | ||
| Q1 25 | $-103.7M | $37.9M | ||
| Q4 24 | $-73.3M | $178.8M | ||
| Q3 24 | $-59.0M | $43.8M | ||
| Q2 24 | $-98.4M | $50.9M | ||
| Q1 24 | $-122.3M | $35.0M |
| Q4 25 | $-61.9M | $191.9M | ||
| Q3 25 | $-89.5M | $51.1M | ||
| Q2 25 | $-74.9M | $48.4M | ||
| Q1 25 | $-109.9M | $36.8M | ||
| Q4 24 | $-77.5M | $169.7M | ||
| Q3 24 | $-61.3M | $41.7M | ||
| Q2 24 | $-98.9M | $49.0M | ||
| Q1 24 | $-126.5M | $31.9M |
| Q4 25 | -71.3% | 114.1% | ||
| Q3 25 | -132.7% | 30.1% | ||
| Q2 25 | -124.9% | 28.7% | ||
| Q1 25 | -222.8% | 23.3% | ||
| Q4 24 | -105.1% | 103.0% | ||
| Q3 24 | -104.6% | 24.5% | ||
| Q2 24 | -317.9% | 31.1% | ||
| Q1 24 | -17685.3% | 20.8% |
| Q4 25 | 10.7% | 3.8% | ||
| Q3 25 | 16.1% | 0.9% | ||
| Q2 25 | 12.4% | 0.8% | ||
| Q1 25 | 12.6% | 0.7% | ||
| Q4 24 | 5.7% | 5.6% | ||
| Q3 24 | 3.9% | 1.2% | ||
| Q2 24 | 1.4% | 1.2% | ||
| Q1 24 | 583.4% | 2.1% |
| Q4 25 | — | 4.65× | ||
| Q3 25 | — | 1.11× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | 4.63× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.29× | ||
| Q1 24 | — | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
PRK
Segment breakdown not available.
